reeclampsia is a multisystemic pregnancy-specifi c disease characterized by endothelial dysfunction.
Furthermore, there are currently no laboratory tests that accurately predict which women will have an adverse outcome. 16 , 17 In this study, we sought to determine whether differences in urinary PRL levels, the presence of antiangiogenic PRL fragments in the urine and circulating levels of sFlt-1, PlGF, and sEng in women presenting with the diagnosis of preeclampsia can identify those patients who are likely to have a more severe condition and a worse maternal outcome.
Patients and Methods
The study was approved by the scientifi c and ethics committees of Instituto Mexicano del Seguro Social, and all participating subjects signed an informed consent. Mild preeclampsia (mPE) was diagnosed when the systolic or diastolic blood pressure were ≥ 140 mm Hg or ≥ 90 mm Hg, respectively, measured twice at least 6 hours apart along with signifi cant proteinuria ( ≥ 300 mg of protein in a 24-hour urine specimen or a protein:creatinine ratio ≥ 0.30 in a random urine sample). 18 Severe preeclampsia (sPE) was considered on fi nding either HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count), eclamspia, or preeclampsia along with severe hypertension (systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 110 mm Hg on at least 2 occasions 6 hours apart) or massive proteinuria ( ≥ 5 g/d or a protein:creatinine ratio ≥ 3.87). 18 Detailed defi nitions have already been published. 11 The adverse maternal outcomes included maternal mortality and any of the following serious maternal morbidities: hepatic hematoma or rupture (confi rmed by ultrasound or laparotomy), pulmonary edema (clinical diagnosis and with radiographic confi rmation), need for positive inotropic support, intubation (other than solely for caesarean section), acute renal failure (creatinine ≥ 198 µ mol/L), and placental abruption (clinical or pathological). The adverse fetal/neonatal outcomes studied included the death (stillbirths [defi ned as death of a fetus] and neonatal death [defi ned as death a newborn until hospital discharge]) and small for gestational age infant (SGA), defi ned as an infant whose birth weight was below the 10th percentile. 19 A random urine sample was collected under sterile conditions and a venous blood sample was simultaneously drawn under basal conditions and without hormonal or drug stimulus. Samples were centrifuged, and the resulting sera and sediment-free urine specimens were aliquoted and stored at − 80 C until assayed. All samples were collected before clinical suspicion or diagnosis confi rmation of any studied adverse outcome. Clinical and delivery outcomes were recorded to classify the patients with preeclampsia. None of the women studied had preexisting hypertension or diabetes mellitus, renal diseases, connective tissue disorders, or other high-risk obstetric condition. All patients were treated according to national guidelines, which are available at http://www. imss.gob.mx/profesionales/guiasclinicas/Documents/020GRR.pdf
PRL Immunoassay
Immunoreactive PRL in serum and urine was determined by an ultrasensitive enzyme immunoassay as described. 20 Urinary PRL levels were normalized for urinary creatinine concentration and expressed as ng of PRL/mg creatinine. Urinary protein and creatinine were measured as previously described.
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Western Blot Analysis
Urine samples of 600 µ L were immunoprecipitated, and the procedure used was similar to that previously reported.
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Serum Analysis
Serum levels of sFlt-1, PlGF, and sEng were determined in duplicate by ELISA (R & D Systems, Minneapolis, MN) following the manufacturer ´ s instructions. The sFlt-1/PGF ratio was calculated from the corresponding sFlt-1 and PlGF values.
Statistical Analysis
Differences between continuous variables were determined by the unpaired Student t test (or the Mann -Whitney U test for non-normally distributed variables). Differences between categorical variables were determined by the Chi-square test with Yates continuity correction or the Fisher exact test for small samples (or the Mantel-Haenszel χ 2 test with linear tendency for variables with > 2 categories). Differences among ≥ 3 continuous variables were determined by 1-way analysis of variance (ANOVA) followed by post hoc procedures (Scheffe test) or by the Kruskal-Wallis 1-way test followed by the Mann -Whitney U test for non-normally distributed variables.
Association between urinary PRL levels, the presence of antiangiogenic PRL fragments in urine, serum sEng levels, and sFlt1/PlGF ratios, and the subsequent risk of adverse outcomes, was calculated. Test results were grouped into quartiles, and the odds ratios (ORs) and 95% confi dence intervals (CIs) were calculated to assess the association between quartiles and the risk of adverse outcomes. The lowest quartile was used as reference category for all biomarkers except for the antiangiogenic PRL fragments (their absence was the reference group). Logistic-regression analysis was used to adjust the ORs for maternal age, gestational age at sampling, body mass index, and smoking status because these variables were signifi cantly different among the groups studied by univariate analysis. In addition, the odds ratios for urinary PRL and antiangiogenic PRL fragments in urine were also adjusted for serum creatinine, serum prolactin, and protein:creatinine ratio. This analysis was necessary considering that these variables may distinctly affect urinary PRL excretion and thereby explain the higher urinary PRL concentrations in preeclamptic women with adverse outcomes. The linear relationship between urinary PRL levels and time elapsed in days between sampling and delivery was assessed by Spearman correlation coeffi cient and linear relationship between sFlt-1/PlGF ratio or serum sEng concentrations, and the interval time in days between sampling and delivery was assessed by Pearson correlation coeffi cient. A 2-tailed P < 0.05 was considered statistically signifi cant.
Results
General Description of the Population Studied
A total of 501 consecutive women with preeclampsia were included in the study. Patients were classifi ed into 3 groups according to clinical severity and delivery outcomes: Group I, patients with mPE (n=122); Group II, sPE, but without HELLP syndrome or eclampsia (n=261); and Group III, sPE with HELLP syndrome or eclampsia (n=118). The demographic, clinical, and obstetric characteristics of the patients are shown in Table 1 . Forty-eight patients had ≥ 1 adverse maternal outcomes, and all were in groups II and III. The occurrence of the combined adverse maternal outcomes and the various individual adverse outcomes, including placental abruption, hepatic hematoma or rupture, acute renal failure, need for inotropic drug support, as well as endotracheal intubation, and maternal death were signifi cantly higher in group III than in group II ( P ≤ 0.03).
Circulating Levels of Angiogenic Factors, Urinary PRL Levels, and the Presence of Antiangiogenic PRL Fragments in Urine Are Associated With the Severity of PE Clinical laboratory results as well as serum concentrations of angiogenic factors, urinary PRL levels, and the presence of antiangiogenic PRL fragments in urine are shown in Table 2 . Urinary PRL levels were signifi cantly higher in group III than in groups I and II ( P < 0.001) and in group II than in group I ( P < 0.001). Antiangiogenic PRL fragments in urine specimens from patients in group I were virtually absent as revealed by the results of Western blotting (Figure) . In contrast, the antiangiogenic PRL fragments (16-or 14-kDa bands) were present in 30/261 (11.5%) specimens from group II ( P < 0.001 monary edema (clinical diagnosis and with radiographic confi rmation), need for positive inotropic support, intubation (other than solely for caesarean section), acute renal failure (creatinine ≥ 198 µ mol/L), and placental abruption (clinical or pathological). The adverse fetal/neonatal outcomes studied included the death (stillbirths [defi ned as death of a fetus] and neonatal death [defi ned as death a newborn until hospital discharge]) and small for gestational age infant (SGA), defi ned as an infant whose birth weight was below the 10th percentile. 19 A random urine sample was collected under sterile conditions and a venous blood sample was simultaneously drawn under basal conditions and without hormonal or drug stimulus. Samples were centrifuged, and the resulting sera and sediment-free urine specimens were aliquoted and stored at − 80 C until assayed. All samples were collected before clinical suspicion or diagnosis confi rmation of any studied adverse outcome. Clinical and delivery outcomes were recorded to classify the relationship between sFlt-1/PlGF ratio or serum sEng concentrations, and the interval time in days between sampling and delivery was assessed by Pearson correlation coeffi cient. A 2-tailed sidered statistically signifi cant.
Results
General Description of the Population Studied
A total of 501 consecutive women with preeclampsia were included in the study. Patients were classifi ed into 3 groups according to clinical severity and delivery outcomes: Group I, patients with mPE (n=122); Group II, sPE, but without HELLP syndrome or eclampsia (n=261); and Group III, sPE with HELLP syndrome or eclampsia (n=118). The demographic, by guest on August 15, 2017 http://hyper.ahajournals.org/ Downloaded from versus group I) and in 64/118 (54.2%) samples from patients in group III ( P < 0.001 versus group I and II).
The median of serum PlGF concentrations was signifi cantly higher in patients from group I than in patients in group II and III ( P < 0.001). Although the median of serum PlGF levels was higher in patients in group II than in group III, the differences were not statistically signifi cant. Serum concentrations of sFlt-1 and sEng and sFlt-1/PlGF ratios differed signifi cantly ( P < 0.001) among groups.
Circulating Angiogenic Factors, Urinary PRL Levels, and the Presence of Antiangiogenic PRL Fragments in Urine and the Risk of Adverse Outcome
The association between quartiles of circulating levels of sEng and sFlt-1/PlGF ratios and urinary PRL levels and risk of combined and specifi c adverse maternal outcomes is shown in Table 3 . Women in the highest quartile for all the studied biomarkers were at a higher risk of combined adverse maternal outcomes. There was a clear association between urinary PRL levels in the highest quartile and higher risk to the occurrence of all specifi c adverse maternal outcomes studied (OR ≥ 5.7). Women in the highest quartile for sFlt-1/PlGF ratio, only exhibited higher risk for placental abruption, need for inotropic drug support and endotracheal intubation (OR ≥ 4.9), whereas women in the highest quartile for serum concentrations of sEng had an increased risk for hepatic hematoma or rupture (OR, 7.3; 95% CI, 1.5 -34.4). For antiangiogenic PRL fragments, there was an increase risk of combined and all specifi c adverse maternal outcomes studied when 14-or 16-kDa PRL isoforms in urine were present, compared with women without these antiangiogenic PRL fragments (OR ≥ 4.7; Table 4 ).
With regard to the adverse perinatal outcomes, there were no signifi cant differences in the risk for stillbirths or neonatal deaths according to quartiles of all biomarkers studied. In contrast, for all biomarkers studied, women in the highest quartile were at higher risk of having a SGA infant than women with values of these biomarkers in the lowest three quartiles. Moreover, women in the second and third quartiles the ORs for having a SGA infant progressively increased, suggesting that the relationship between values of each biomarker and risk of SGA infant has a linear dose -response pattern ( Table 3 ) . Similarly, women with the presence of 14-or 16-kDa PRL isoforms in urine had an increased risk for SGA infant, but not for stillbirths or neonatal deaths ( Table 4 ) .
Circulating Angiogenic Factors and Urinary PRL Levels and Pregnancy Duration From Sampling to Delivery
The correlation between measurements of urinary PRL and time elapsed between sampling and delivery was negative and signifi cant (r s = -0.68, P < 0.001); this relationship was less for the sFlt-1/PlGF ratio and concentrations of sEng ( r = -0.56, P < 0.001 and r = -0.53, P < 0.001, respectively).
Discussion
The present study, involving a large number of preeclamptic women with a wide spectrum of disease severity, demonstrates that alterations in circulating angiogenic are associated with the severity of preeclampsia. Our results are consistent with previous reports and provide further support to the notion that alterations of these angiogenic factors not only do occur in women with preeclampsia but also that these biochemical abnormalities become more pronounced as the severity of the disease increases, particularly when preeclampsia occurs preterm. 5 -8 We also showed that higher urinary PRL levels and ALT indicates alanine amino transferase; AST, aspartate amino transferase; LDH, lactate deshydrogensase; PlGF, placental growth factor; PRL, prolactin; sEng, soluble endoglin; and sFlt-1, soluble fms-tyrosine kimase-1. P value is given only for signifi cant differences: * vs women with mild preeclampsia or † vs women with severe preeclampsia after application of appropriate statistical tests.
Figure.
Representative Western blot of immunoreactive prolactin (PRL) in urine. Samples were immunoprecipitated with specifi c human PRL (hPRL) antisera and subjected to SDS-PAGE under reducing conditions. All blots were probed with an anti-hPRL monoclonal antibody. Urine samples from patients with mild preeclampsia ( A ) and urine samples from patients with severe preeclampsia ( B ). NC indicates negative control; and Std, human pituitary PRL standard (100 ng). The numbers on the left indicate the position of the molecular weight markers. The estimated relative molecular mass (M r ) of each band is shown on the right .
In contrast, for all biomarkers studied, women in the highest quartile were at higher risk of having a SGA infant than women with values of these biomarkers in the lowest three suggesting that the relationship between values of each biomarker and risk of SGA infant has a linear dose -response pattern ( Table 3 ) . Similarly, women with the presence of 14-or ALT indicates alanine amino transferase; AST, aspartate amino transferase; LDH, lactate deshydrogensase; PlGF, placental growth factor; PRL, prolactin; sEng, soluble endoglin; and sFlt-1, soluble fms-tyrosine kimase-1. P value is given only for signifi cant differences: * vs women with mild preeclampsia or † vs women with P value is given only for signifi cant differences: * vs women with mild preeclampsia or † vs women with P severe preeclampsia after application of appropriate statistical tests. Preeclamptic women whose sFlt-1/PlGF ratio and sEng or urinary PRL levels fall within the highest quartile or who have antiangiogenic PRL fragments in urine showed an increased risk of combined maternal adverse outcomes or having a SGA infant even after taking into account gestational age at delivery, maternal age, body mass index, smoking status, protein:creatinine ratio, and serum levels of creatinine and PRL. Further, we identifi ed that both urinary PRL levels and the presence of antiangiogenic PRL fragments in urine are superior to circulating concentrations of sFlt-1/PlGF ratio and sEng in predicting the risk of combined adverse maternal outcomes, as well as of all specifi c adverse outcomes studied. We thus have confi rmed and extended previous observations 21 , 22 as to the association between the circulating sFlt-1/PlGF ratio at the time of initial evaluation and subsequent adverse outcomes in women with singleton or twin pregnancies with suspected preeclampsia; additionally, those studies found an inverse correlation between the sFlt-1/PlGF ratio and the time elapsed between presentation and delivery as we did in the present study. However, we found a greater negative correlation between urinary PRL levels and time elapsed between sampling and delivery when compared with the sFlt-1/PlGF ratio or serum concentrations of sEng. In contrast to the data presented herein, those previous studies failed to fi nd an increased risk for the development of any individual adverse outcomes in women with elevated sFlt-1/PlGF ratios. This discrepancy may stem from differences in the population and the limited sample size of alternative adverse outcomes studied.
More importantly is our fi nding that both urinary PRL levels and the presence of antiangiogenic PRL fragments in urine markedly improve the sensitivity to predict either combined or specifi c adverse maternal outcomes or SGA infant risk when compared with the circulating concentrations of sFlt-1/PlGF ratios or sEng. The latter is consistent with other studies revealing very high urinary PRL levels and frequently detected antiangiogenic PRL fragments in preeclamptic women with placental abruption, acute renal failure, and pulmonary edema 11 , as well as inverse correlation between the concentration of antiangiogenic PRL fragments in the amniotic fl uid of preeclamptic women and infant birth weight. 14 It has recently been suggested that antiangiogenic PRL fragments may indeed contribute to the pathogenesis of preeclampsia, rather than representing merely a biomarker of the condition.
11 , 14 It has been suggested that the antiangiogenic PRL fragments found in this context result from an increased proteolytic cleavage of monomeric or intact 23-kDa PRL by CI indicates confi dence interval; OR, odds ratio; PlGF, placental growth factor; PRL indicates prolactin; sEng, soluble endoglin; and sFlt-1, soluble fms-like tyrosine kinase-1. Odds ratios were adjusted for maternal age, gestational age, body mass index, and smoking. In addition, the odds ratios for urinary PRL were also adjusted for serum creatinine, serum prolactin, and protein:creatinine ratio.
* The reference OR is the frequency of adverse outcomes in quartile 1 to 3 combined. ND denotes situations in which OR could not be determined, because all measurements from women with that adverse outcome were located in the highest quartile. CI indicates confi dence interval; OR, odds ratio; PlGF, placental growth factor; PRL indicates prolactin; sEng, soluble endoglin; and sFlt-1, soluble fms-like tyrosine kinase-1. Odds ratios were adjusted for maternal age, gestational age, body mass index, and smoking. In addition, the odds ratios for urinary PRL were also adjusted for serum creatinine, serum prolactin, and protein:creatinine ratio.
* The reference OR is the frequency of adverse outcomes in quartile 1 to 3 combined. ND denotes situations in which OR could not be determined, because all measurements from women with that adverse outcome were located in the highest quartile. by guest on August 15, 2017 http://hyper.ahajournals.org/ Downloaded from cathepsin-D, a lysosomal aspartyl protease, which is present in almost all cells, tissues, and organs, including endothelial cells, placenta, kidney, and heart. 23 In fact, the posttranslational modifi cations of PRL are among the mechanisms implicated in the functional diversity of PRL. The 14-and 16-kDa PRL fragments exhibit antiangiogenic effects both in vitro and in vivo, 9 , 13 and it has been demonstrated that the antiangiogenic PRL fragments block the biological activity of vascular endothelial growth factor (VEGF). 17 , 24 In addition, it has been demonstrated that the expression of antiangiogenic PRL fragments is increased in placental tissue through the action of throphoblast cathepsin-D, which is upregulated in preeclampsia, but not in placentas from normotensive pregnancies. 14 , 15 Furthermore, it has been demonstrated that antiangiogenic PRL fragments in amniotic fl uid and urine from patients with preeclampsia are not processed locally, despite high PRL concentrations; rather, they appear to derive from placental tissue and the glomerular endothelium. 11 , 14 Thus, the presence of antiangiogenic PRL fragments in amniotic fl uid, urine, and serum may refl ect a local increased generation by placenta, kidney, vascular endothelial cells, and heart by an increased endogenous cathepsin-D activity in response to oxidative damage and their subsequent leakage to those biological fl uids.
Taken together, these data suggest that perturbation of other pathways may be necessary for the development and progression of the clinical manifestation of preeclampsia and may have an additive effect that leads to alterations in cellular functions and contribute to endothelial dysfunction, and subsequently, of the development of adverse outcomes.
The strengths of our study include a well-defi ned, large population of women with preeclampsia (ie, with hypertension and signifi cant proteinuria as criteria to be included in the present study, regardless of other clinical and laboratory data) who had received the same standardized medical protocol, and the fact that all samples were collected before severity classifi cation of preeclampsia and clinical suspicion or diagnostic confi rmation of adverse maternal and perinatal outcomes, which evidently avoided a selection bias. On the other hand, we are aware of the presence of certain limitations. First, we cannot generalize our fi ndings to women with pregnancy-associated hypertension without signifi cant proteinuria or to pregnant women at high risk for adverse outcomes, such as chronic hypertension, pregestational diabetes mellitus, renal diseases, autoimmune disorders, or other health conditions. Secondly, given the cross-sectional design of our study it would be inappropriate to establish a defi nitive causal relationship between our biochemical fi ndings and the severity of preeclampsia and its adverse outcomes. Further prospective longitudinal studies are still needed to establish the temporal profi le and behavior of these biomarkers as well as to elucidate the origin of antiangiogenic PRL isoforms.
Finally, uncovering the mechanism of altered generation of antiangiogenic PRL fragments in preeclampsia may also provide insights into novel therapeutic options. Our results may constitute the necessary biochemical framework to support clinical trials to determine whether the use of dopamine agonists to block the secretion of PRL by the anterior pituitary or the use of inhibitors of cathepsin-D can ameliorate or prevent endothelial dysfunction and the preeclampsia syndrome.
In conclusion, our results demonstrate that circulating concentrations of sFlt-1/PlGF and sEng, and urinary PRL levels as well as the presence of antiangiogenic PRL fragments in urine, are associated with preeclampsia severity at the time of clinical manifestation and may be used to identify the occurrence of adverse outcomes in preeclamptic women.
Perspectives
Preeclampsia remains a major cause of maternal and perinatal morbidity and mortality worldwide. Preeclampsia-related adverse outcomes could be prevented if we could predict them. Here, we report that the sFlt-1/PlGF ratio, sEng concentrations, and urinary PRL levels and its antiangiogenic PRL fragments are highly associated with subsequent maternal and perinatal adverse outcomes. Furthermore, that urinary PRL levels and the presence of antiangiogenic PRL fragments appear to be better biomarkers than either the sFlt-1/PlGF ratio or sEng. Urinary PRL levels or its antiangiogenic PRL fragments might be useful to monitor adverse outcomes risk in women with preeclampsia, especially when it occurs preterm with the objective to prolong pregnancy, to improve outcomes, and reduce health care costs. Uncovering the mechanisms for altered generation of the antiangiogenic PRL fragments in preeclampsia may also provide insights into novel therapeutic options. 
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